TELEPHONE SUPPORT FOR SCHEDULED GRADUAL REDUCTION

描述：虽然大多数吸烟者喜欢自己戒烟，但许多吸烟者仍然需要戒烟帮助，并对此感兴趣。电话咨询是提供戒烟帮助的一种流行方式。维护现场电话支持计划的成本很高。然而，现代技术已经产生了新的选择，而不仅仅是现场电话咨询。交互式语音应答(IVR)是一种能够以低成本提供与吸烟者变化阶段相匹配的大量电话消息的系统。在这个第一阶段的项目中，我们建议开发和评估一个IVR电话计划，以支持LifeSign的使用。该计划将包括(1)一台易于使用的信用卡大小的LifeSign计算机；(2)一份节目指南；(3)由IVR产生的主动电话支持。在第一阶段，我们将开发IVR系统的原型，为LifeSign提供主动电话支持。它将在一项为期10周的可行性研究中进行评估，N=100名受试者被随机分配到两种情况之一：(1)有电话支持的LifeSign或(2)仅有LifeSign作为对照。令人感兴趣的主要结果指标包括10周后经过生化验证的戒烟率，以及吸烟率和一氧化碳水平较基线水平的下降。将根据计算机生成的遵约数据的处理和处理结果以及用户对IVR电话支持的满意程度来评估可行性。在第二阶段，将开发该计划的第二代原型，并在更大规模的临床试验中进行评估。

DESCRIPTION: While most smokers prefer to quit on their own, many smokers continue to need and be interested in smoking cessation assistance. Telephone counseling is a popular way of delivering cessation assistance. The cost of maintaining live telephone support programs is expensive. However, modern technology has produced new options that go beyond live telephone counseling. Interactive voice response (IVR) is one system that can offer a large array of telephone messages matched to the smokers' stage of change at a low cost. In this Phase I project, we propose to develop and evaluate an IVR telephone program to support use of LifeSign. The program will consist of (1) an easy to use, credit card sized LifeSign computer; (2) a Program Guide, and (3) proactive telephone support generated by IVR. During Phase I, we will develop the prototype of an IVR system to provide proactive telephone support for LifeSign. It will be evaluated in a 10-week feasibility study with N=100 subjects randomly assigned to one of two conditions: (1) LifeSign with Telephone Support or (2) LifeSign alone as the control. The primary outcome measures of interest include biochemically verified abstinence rates at 10-week follow-up and reductions from baseline in smoking rate and carbon monoxide levels. Feasibility will be evaluated on the basis of treatment and process outcomes of computer-generated compliance data and measures of user satisfaction with IVR telephone support. During Phase II, a second-generation prototype of the program will be developed and evaluated in a larger scale clinical trial.